Menu

Tau Production Increased in Alzheimer’s Patients

The findings suggest that faster synthesis, rather than decreased clearance, causes the protein to build up in neurons.

Mar 21, 2018
Jim Daley

Tau protein tangles in the hippocampus of a person with Alzheimer-related pathologyWIKIMEDIA, PATHO

People with Alzheimer’s have a higher production rate of tau proteins than healthy individuals, according to a study published today (March 21) in Neuron.

While researchers have long known that tau levels are elevated in the brains and cerebrospinal fluid of Alzheimer’s patients, “until this study, we didn’t know if tau production was increased or if clearance was decreased,” coauthor Chihiro Sato, a researcher in neurologist Randall Bateman’s lab at Washington University School of Medicine, says in a statement. “Our results showing that tau production is increased suggest that we might want to target tau production therapeutically.”

See “Probing the Role of Tau Protein in Disease

Sato, Bateman, and their colleagues measured the turnover rate of tau in the cerebrospinal fluid of people with Alzheimer’s and healthy controls. When they compared the two groups, they discovered that study participants with Alzheimer’s were producing tau at faster rates than those without the disease.

The researchers also examined tau production in neurons made from induced pluripotent stem cells and found that forms of the protein that were prone to folding errors also have higher turnover rates than others.  

“This study changes our way of thinking about tau in the context of neurodegenerative diseases,” Bateman says in the statement. “We expect these findings will help us to distinguish between Alzheimer’s and other types of tauopathies in future.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.